Active Not RecruitingNCT05733546
COMP360 for recurrent depression: safety and tolerability
About this title
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Read the official source — NCT05733546Medication studyAges 18+United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- La Jolla and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 30, 2023
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 102
- Sponsor
- COMPASS Pathways
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT05733546
- Official title
Show the full official title
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Recruitment & locations
Not recruitingLa Jolla · Jacksonville · Rockville
2 more locations
- Springfield
- Plano
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is COMPASS Pathways.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
